Kidney Calculi
Conditions
Brief summary
The rationale for this study is to determine if there is a difference in complications among patients undergoing ureteroscopy for renal stones who receive a stent compared to not receiving a stent postoperatively.
Detailed description
Kidney stones affect 9% individuals within the United States, and the prevalence is increasing. Over the last few decades, ureteroscopy has become the most commonly performed stone procedure. However the complication rate after ureteroscopy is not insignificant. Reducing morbidity after ureteroscopy would improve patient outcomes and reduce health care utilization. A major contributor to patient morbidity after ureteroscopy is the ureteral stent, which is placed at the time of surgery and left in place 1-2 weeks after surgery. The rationale for utilizing stents is to prevent urinary obstruction from edema or stone fragments. On the other hand, stents cause hematuria, pain, and lower urinary tract symptoms. Additionally, stent-related symptoms are often misdiagnosed as urinary tract infections leading to unnecessary antibiotic use. The clinical utility of ureteral stents after ureteroscopy has not been well studied, specifically a stone located in the kidney. Prior studies on stent-less ureteroscopic procedures have focused on treatment of ureteral stones and not stones located in the kidney, have had restrictive inclusion and exclusion criteria, are primarily from single center institutions, and most being performed \ 15 years ago. Surgical techniques and device innovations have changed the procedure since that time. To date, there have been only 2 studies that included stone located in the kidney showing no difference in unplanned hospital revisits, however both combined analyses with ureteral stones and selection bias was an issue for both studies. In addition, there is a lack of studies assessing opiate use, impact of quality of life with stent placement, and loss of work related to stent placement
Interventions
PROCEDUREUreteroscopy
Ureteroscopy for 1.5cm or less renal stones.
Sponsors
Vanderbilt University Medical Center
Université de Montréal
University of California, Davis
University of California, San Diego
Indiana University
Brigham and Women's Hospital
Penn State Health
University of California, Los Angeles
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* nonobstructing renal stone 1.5cm total stone diameter (if multiple stones, then sum of maximum diameters) or less undergoing ureteroscopy
Exclusion criteria
* age \< 18 years * pregnancy status * ureteral stone * preoperative hydronephrosis * indwelling nephrostomy tube * planning bilateral ureteroscopy or subsequent staged ureteroscopy * solitary kidney or eGFR \<60 mL/min (CKD stage 3 or greater) * variant anatomy including horseshoe kidney, pelvic kidney, prior urinary tract reconstruction
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Total number of complications | 30 days after ureteroscopy | Total number of complications - Defined as ER visits related to procedure, unanticipated provider visit, and hospitalization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PROMIS (Patient-Reported Outcomes Measurement Information System) form 6a | baseline to 5-10 days after ureteroscopy | This survey assesses self-reported consequences of pain on relevant aspects of one's life, including engagement with social, cognitive, emotional, physical, and recreational activities. There are 6 questions on the survey. The survey score uses at T-score metric with a mean of 50 and a standard deviation of 10 in a referent population. A higher score denotes greater pain interference in one's life. |
| WISQOL (Wisconsin Stone Quality of Life Questionnaire) | baseline to 5-10 days after ureteroscopy | This is a disease specific quality-of-life instrument designed to assess the impact on patients of stones in the urinary tract. The survey is a 28-item instrument with a 5-point LIkert scale for each item. There are a total of 140 points total, and a difference of 10 points can be considered clinically significant. |
| Cumulative opiate morphine equivalent dosing (MED) | baseline to 5-10 days after ureteroscopy | This will be the calculated morphine equivalent dosage of all opiate medications that are prescribed after surgery to follow-up at 5-10 days. |
| % return to work | 5-10 days after ureteroscopy | This is the number of participants that have returned to work at the time of follow-up at 5-10 days divided by the total participants in the group. |
| Number of participants with symptomatic urinary tract infection (UTI) | Baseline 5-10 days after ureteroscopy | This will be defined as a urine culture positivity (50,000 cfu/mL or more) with urinary symptoms. |
| Number of participants with abnormal imaging findings | 4-8 weeks after ureteroscopy | Hydronephrosis, hematoma, urinoma on routine postop imaging |
Countries
Canada, United States
Contacts
PRINCIPAL_INVESTIGATORRyan Hsi, MD
Vanderbilt University Medical Center
Outcome results
None listed